Every material Form 8-K Marsh McLennan filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Marsh McLennan reported third-quarter 2025 results, with revenue of $6.4 billion, up 11% from a year earlier (4% on an underlying basis). GAAP earnings per share were $1.51, flat with the prior-year quarter, while adjusted EPS rose 11% to $1.85. Shareholders also learned that the company's NYSE ticker will change from MMC to MRSH in January 2026, and that its businesses will adopt the Marsh brand.
Q3 2025 revenue $6.4 billion, up 11% (4% underlying); operating income rose 6% to $1.2 billion
GAAP EPS $1.51 versus $1.51 a year earlier; adjusted EPS $1.85, up 11%
Repurchased about 1.9 million shares for $400 million in Q3; $1.0 billion repurchased in the first nine months
Stock ticker changes from MMC to MRSH on the NYSE in January 2026
Marsh & McLennan reported second quarter 2025 results on July 17, 2025. Revenue rose 12% to $7.0 billion, or 4% on an underlying basis, while GAAP diluted EPS rose 8% to $2.45 and adjusted EPS rose 11% to $2.72. The company also said its Board recently raised the quarterly dividend 10% to $0.900 per share.
Second quarter revenue of $7.0 billion, up 12%; underlying revenue growth of 4%
Net income attributable to the Company of $1.2 billion; diluted GAAP EPS of $2.45 versus $2.27 a year earlier
Adjusted EPS of $2.72, up 11% from $2.44 a year earlier
Quarterly dividend increased 10% to $0.900 per share; third quarter dividend payable August 15, 2025
Marsh McLennan's board appointed Bruce Broussard as an independent director, effective immediately, and also named him to the Audit Committee. The company's press release says the board now has 12 directors, and Broussard is a former Humana CEO, which gives the board healthcare and insurance experience.
Appointment effective July 9, 2025, as an independent, non-management director
Broussard also joins the Audit Committee; the board determined he meets its independence requirements
Press release says Broussard was Humana's CEO from 2013 to 2024 and serves on the HP Inc., Cleveland Clinic and One Call boards
Board now consists of 12 directors, per the press release
Marsh McLennan reported first quarter 2025 results on April 17, 2025. Revenue rose 9% to $7.1 billion, or 4% on an underlying basis, but GAAP earnings per share fell 1% to $2.79, while adjusted EPS rose 5% to $3.06. The company also repurchased $300 million of stock and repaid $500 million of senior notes during the quarter.
Revenue of $7.1 billion, up 9% from the first quarter of 2024; underlying revenue growth of 4%
GAAP EPS of $2.79, down 1%; adjusted EPS of $3.06, up 5%, including a 10-cent benefit from favorable discrete tax items
Repurchased 1.3 million shares for $300 million in the first quarter
Repaid $500 million of senior notes that matured in March
Marsh & McLennan reported fourth-quarter and full-year 2024 results on January 30, 2025, in a press release furnished under Item 2.02. Full-year revenue rose 8% to $24.5 billion and GAAP earnings per share rose 9% to $8.18, while fourth-quarter revenue rose 9% to $6.1 billion. The filing does not include 2025 guidance.
Q4 2024 revenue $6.1 billion, up 9%; Q4 GAAP EPS $1.59, up 5%
Full-year 2024 revenue $24.5 billion, up 8%; GAAP EPS $8.18, up 9%
Full-year adjusted EPS $8.80, up 10%, per the company's non-GAAP measure
Company repurchased 4.3 million shares for $900 million in 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Marsh McLennan filing is on SEC EDGAR ↗. 8-K briefs of other companies →